title: Ponatinib pulled off market over safety issues.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Dalzell
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D011724:Pyridazines / Q000009:adverse effects*; D056737:Safety-Based Drug Withdrawals; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D011724:Pyridazines; C545373:ponatinib